SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Ida B. Wells — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientIda B. Wells
Date of birth1862-07-16
IdentifiersMRN HR-ET022-SYN-TD; SSN (made up) 000-22-5903
Document date1931-03-03
AuthorCordelia Ashworth-Banks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months ahead. [S]

History of Present Illness

Mrs. Wells returns two weeks after her annual wellness visit and four weeks after starting dapagliflozin. She has had no dizziness, genital itching or sick days. Her home readings average 130/78. Her ankles have not swollen for three weeks and her afternoons are easier, though she still tires on long writing days. Since the kidney education session she has written down her questions about transplant evaluation for her next nephrology visit. She asked for the COVID-19 vaccine today. [S]

ElementDetail
Home blood pressureAverage 130/78
Side effectsNone
SymptomsNo ankle swelling; less tired

Review of Systems

SystemResultFinding
ConstitutionalPositiveLess tired; tires on long writing days
CardiovascularNegativeNo ankle swelling
GenitourinaryNegativeNo burning or genital itching
NeurologicalNegativeNo dizziness

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxenOne or two tablets up to three times a day as neededOral route1931-01-05activeS
Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eatingOne tablet daily, with sick-day rulesOral route1931-01-20 to 1931-03-03completedS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1931-01-20activeS
Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet dailyOne tablet dailyOral route1931-01-20activeS
Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgeryOne tablet daily, with sick-day rulesOral route1931-02-03activeS
Losartan 100 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eatingOne tablet daily, with sick-day rulesOral route1931-03-03activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1931-03-03Body height157cmS
1931-03-03Body weight68.9kgS
1931-03-03Body mass index (BMI) [Ratio]28kg/m2S
1931-03-03Systolic blood pressure132mm[Hg]S
1931-03-03Diastolic blood pressure80mm[Hg]S
1931-03-03Heart rate72/minS
1931-03-03Respiratory rate16/minS
1931-03-03Body temperature36.6CelS
1931-03-03Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1931-03-03Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1931-03-03Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
1931-03-03Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/LKeep at 22 or above in kidney diseaseNormalS
1931-03-03Urea nitrogen [Mass/volume] in Serum or Plasma31mg/dL8-23 mg/dLHighS
1931-03-03Creatinine [Mass/volume] in Serum or Plasma1.56mg/dL0.59-1.04 mg/dLHighS
1931-03-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1926)/1.73 sq M36mL/min/{1.73_m2}60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4LowS

Physical Exam

Vital signs recorded on 1931-03-03; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 132/80, pulse 72; weight 68.9 kg
CardiovascularRegular rhythm; no ankle swelling

Problems

ProblemClinical statusVerificationCodeProvenance
Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be establishedresolvedconfirmed R94.4S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks.
Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Hypertension, stage 2, confirmed by home readings (average 150/88 mmHg), with chronic kidney diseaseactiveconfirmed I12.9S — Synthetic modern diagnosis; no blood pressure from her life is recorded.
Chronic kidney disease G3b A2 (eGFR 38 by creatinine and cystatin C, urine albumin-to-creatinine ratio 240 and 228 mg/g), present at least two years; small, echogenic kidneys without obstruction; most likely hypertensive kidney disease, with APOL1-associated disease possible; 5-year kidney failure risk about 7%activeconfirmed N18.32S — Synthetic modern diagnosis linked to the kidney disease recorded at her death.
Anemia of chronic kidney disease, mild (hemoglobin 11.2 g/dL) with adequate iron stores; a likely part of her tirednessactiveconfirmed D63.1S — Synthetic laboratory finding.
Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) with a mildly raised PTH (84 pg/mL); calcium and phosphate normalactiveconfirmed E55.9S — Synthetic laboratory finding, part of the mineral and bone check in kidney disease.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationStandardized office blood pressure (five minutes' rest, validated cuff, average of two readings)Every visitCompleted today132/80
Self-managementHome blood pressure readingsSeven days to confirm; then the week before each visit while medicines changeCompleted todayAverage 130/78
LaboratoryPotassium, sodium, bicarbonate, urea nitrogen, creatinine and eGFRTwo to four weeks after starting or increasing an ARB or SGLT2 inhibitor; then with each eGFR check (about twice a year at G3b A2)Completed todayFour weeks after dapagliflozin: sodium 139, potassium 4.8, bicarbonate 23 mmol/L; urea nitrogen 31, creatinine 1.56 mg/dL; eGFR 36. Repeat two to four weeks after today's losartan increase
LaboratoryUrine albumin-to-creatinine ratioRepeat to confirm; three to six months after a treatment change; then about twice a year at G3b A2DueThree months after treatment began
Medication safetyMedication review: NSAIDs, contrast, dose adjustment, sick-day rulesEvery visitCompleted todayNo NSAIDs; medicines checked for kidney dosing
Medication safetyMedicine safety: dizziness, genital infection, urine volume, sick-day rulesAfter starting an SGLT2 inhibitorCompleted todayNo dizziness, genital infection or sick days
LaboratoryHemoglobinAt least yearly at G3; recheck in three months when mildly lowDueAt three months
LaboratoryCalcium, phosphate, intact PTH and 25-hydroxyvitamin DBaseline at G3; then every 6 to 12 months; vitamin D and PTH three months after starting replacementDuePTH and vitamin D at three months on vitamin D3
Medication safetyVaccines for kidney disease (influenza, pneumococcal, hepatitis B, COVID-19)Review yearly; hepatitis B series if not immuneCompleted todayCOVID-19 vaccine today; influenza, PCV20, hepatitis B series, RSV and zoster dose 1 done; zoster dose 2 due in two to six months; hepatitis B antibody check due
ReferralNephrologyWhen 5-year kidney failure risk is 3 to 5% or more, eGFR falls quickly, or the cause is unclearDueReview with Dr. Lindqvist-Moore at three months

Goal progress:

Immunizations given today: COVID-19 vaccine, mRNA, this season [S]

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Potassium and creatinine in two to four weeks. Review with the urine albumin, hemoglobin, PTH and vitamin D in three months, and nephrology review then. Call for dizziness, vomiting or diarrhea (hold losartan and dapagliflozin that day), or swelling of the lips or tongue (call 911). [S]